ANALYST-UPGRADE filed Jul 1, 2026 at 04:33 ET
Baird initiated coverage on Abbott Laboratories (ABT) at Outperform with a $121 price target, implying 33% upside from the current $90.74. The firm has a 54% accuracy rate across 2,555 calls. Consensus is heavily bullish at 70.6% Buy (24 of 34 analysts), with a mean target of $116.54. The PT range spans $92 (low) to $135 (high). Recent EPS revisions have tilted slightly negative over 30 days, but insider buying of ~$1.3M in late April through early May signals confidence. Institutional activity shows large additions from Charles Schwab and Capital Research. With earnings due July 15, the call aligns with consensus direction but adds a fresh bullish catalyst. Bottom line: the initiation reinforces the value case at current levels.